RxSight, Inc.
NASDAQ•RXST
CEO: Dr. Ronald M. Kurtz M.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-30
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
連絡先情報
時価総額
$302.48M
PER (TTM)
-7.8
26.6
配当利回り
--
52週高値
$27.13
52週安値
$6.32
52週レンジ
順位59Top 87.6%
2.2
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q4 2025 データ
売上高
$32.61M+0.00%
直近4四半期の推移
EPS
-$0.22+0.00%
直近4四半期の推移
フリーCF
$17.09M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Gross Margin Improvement Gross Profit reached $103.0M, up 4.1%; favorable LAL sales mix improved gross margin to 76.6%.
LAL Utilization Growth LAL sales increased 11,560 units year-over-year, driven by expanding installed base of 1,134 LDD units.
Strong Cash Position Total cash and short-term investments stand at $228.1M as of December 31, 2025, ensuring liquidity.
Adoption Milestones Reached Nearly 300,000 LALs implanted since inception through year-end 2025, validating commercial traction and adoption efforts.
リスク要因
Sales Volume Decline Total Sales decreased 3.9% to $134.5M, primarily due to 47% drop in LDD unit sales for the year.
Widening Operating Loss Operating Loss widened 30.7% to $(48.2M) as SG&A expenses increased 11.1% to $112.7M.
Pending Litigation Exposure Facing securities class action and shareholder derivative lawsuits; adverse resolution could materially impact business.
Intense Market Competition Primary competitors (Alcon, J&J) control 75% of U.S. premium IOL market, posing intense competition risk.
見通し
Focus on Revenue Growth Commercial realignment initiatives focus on renewed revenue growth via increased LAL utilization at existing practices.
Increased R&D Investment R&D spending increased 12.2% to $38.5M, targeting clinical outcomes, customer experience, and cost reduction.
Selective International Expansion Planning selective international expansion, holding regulatory approvals in Europe, Canada, Mexico, and Asia markets.
Capital Sufficiency Confirmed Expect current cash reserves of $228.1M to fund operations for at least the next 12 months.
同業比較
売上高 (TTM)
$329.52M
$236.35M
$212.69M
粗利益率 (最新四半期)
91.5%
85.5%
80.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BFLY | $967.60M | -12.5 | -35.3% | 6.9% |
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
| TCMD | $604.28M | 31.6 | 9.3% | 5.8% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-4.9%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月12日
EPS:-$0.31
|売上高:$29.97M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし